51
|
Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. Mov Disord 2010; 25:2-12. [DOI: 10.1002/mds.22519] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
52
|
Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8:464-74. [PMID: 19375664 DOI: 10.1016/s1474-4422(09)70068-7] [Citation(s) in RCA: 1104] [Impact Index Per Article: 73.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Several studies, including work from the Parkinson's disease (PD) non-motor group and others, have established that the non-motor symptoms of PD are common, occur across all stages of PD, are under-reported, and are a key determinant of quality of life. Research suggests that the non-motor symptoms of the disease are frequently unrecognised by clinicians and remain untreated. Even when identified, there is a common perception that many of these symptoms are untreatable. The role of dopaminergic drugs in treating the various non-motor problems of PD, although clinically recognised, has received little attention. In this Review, we investigate the dopaminergic basis of the range of non-motor symptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sleep behaviour disorder), and erectile dysfunction. We discuss the evidence that these symptoms are treatable, at least in part, with various dopaminergic strategies and, where relevant, we also refer to the use of deep-brain stimulation of appropriate targets in the brain. This Review provides a comprehensive overview of the management of this challenging aspect of PD.
Collapse
Affiliation(s)
- K Ray Chaudhuri
- National Parkinson Foundation Centre of Excellence, King's College Hospital and University Hospital Lewisham, London, UK.
| | | |
Collapse
|
53
|
Benign Prostatic Obstruction and Parkinson's Disease—Should Transurethral Resection of the Prostate be Avoided? J Urol 2009; 181:2209-13. [DOI: 10.1016/j.juro.2009.01.049] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2008] [Indexed: 01/23/2023]
|
54
|
Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson's disease: A review. Parkinsonism Relat Disord 2009; 15:81-7. [DOI: 10.1016/j.parkreldis.2007.10.016] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2007] [Revised: 10/22/2007] [Accepted: 10/24/2007] [Indexed: 01/26/2023]
|
55
|
Seseke S, Baudewig J, Kallenberg K, Ringert RH, Seseke F, Dechent P. Gender differences in voluntary micturition control — An fMRI study. Neuroimage 2008; 43:183-91. [DOI: 10.1016/j.neuroimage.2008.07.044] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2007] [Revised: 07/16/2008] [Accepted: 07/20/2008] [Indexed: 11/26/2022] Open
|
56
|
Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm (Vienna) 2008; 115:443-60. [PMID: 18327532 DOI: 10.1007/s00702-007-0855-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2007] [Accepted: 11/01/2007] [Indexed: 12/14/2022]
Abstract
Bladder dysfunction (urinary urgency/frequency) and bowel dysfunction (constipation) are common non-motor disorders in Parkinson's disease (PD). In contrast to motor disorder, the pelvic autonomic dysfunction is often non-responsive to levodopa treatment. Brain pathology mostly accounts for the bladder dysfunction (appearance of overactivity) via altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex. In contrast, peripheral enteric pathology mostly accounts for the bowel dysfunction (slow transit and decreased phasic contraction) via altered dopamine-enteric nervous system circuit, which normally promotes the peristaltic reflex. In addition, weak strain and paradoxical anal contraction might be the results of brain pathology. Pathophysiology of the pelvic organ dysfunction in PD differs from that in multiple system atrophy; therefore it might aid the differential diagnosis. Drugs to treat bladder dysfunction in PD include anticholinergic agents. Drugs to treat bowel dysfunction in PD include dietary fibers, peripheral dopaminergic antagonists, and selective serotonergic agonists. These treatments might be beneficial not only in maximizing patients' quality of life, but also in promoting intestinal absorption of levodopa and avoiding gastrointestinal emergency.
Collapse
Affiliation(s)
- R Sakakibara
- Department of Internal Medicine, Toho University, Sakura, Japan.
| | | | | | | | | |
Collapse
|
57
|
|
58
|
Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007; 197:96.e1-5. [PMID: 17618775 DOI: 10.1016/j.ajog.2007.04.016] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2006] [Revised: 01/22/2007] [Accepted: 04/14/2007] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Sacral nerve neuromodulation (SNS) is an effective treatment for lower urinary tract dysfunction. Many underlying neurologic processes affect lower urinary tract function. We present results of SNS in patients with underlying neurologic dysfunction. STUDY DESIGN This is a retrospective case series of 33 patients with neurologic disease and lower urinary tract dysfunction who underwent an InterStim stimulation procedure. Results were evaluated by pre- and postoperative voiding diaries. Success was defined as greater than 50% improvement. RESULTS Twenty-eight of 33 patients (85%) underwent implantation: 13 of 16 (81%) multiple sclerosis, 4 of 6 (67%) Parkinson disease, and 11 of 11 (100%) other neurologic disorders. Incontinence episodes per 24 hours decreased 68%, number of voids per 24 hours decreased 43%, nocturia decreased 70%, and there was a 58% reduction in intermittent self-catheterization per 24 hours. Ninety-three percent reported overall satisfaction. CONCLUSION Sacral nerve neuromodulation is an effective treatment for lower urinary tract dysfunction in patients with underlying neurologic disease.
Collapse
Affiliation(s)
- Patricia A Wallace
- Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, University of California, Irvine, School of Medicine, Orange, CA 92868, USA.
| | | | | |
Collapse
|
59
|
|
60
|
Vassel P, Robain G, Pichon J, Chartier-Kastler E, Ruffion A. Chapitre I - Troubles vésico-sphintériens des syndromes parkinsoniens. Prog Urol 2007; 17:393-8. [PMID: 17622065 DOI: 10.1016/s1166-7087(07)92336-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Lower urinary tract dysfunction is frequent in Parkinson's disease and other Parkinsonian syndromes and can cause urinary incontinence complicating a urgency-frequency syndrome or on the contrary, dysuria. These disorders are a frequent urological presenting complaint due to their impact on the patient's quality of life. Urologists must be aware of the different natural histories of diseases such as Parkinson's disease and Parkinsonian syndromes such as multisystem atrophy, which often have a severe course and are marked by resistance to neuropharmacological treatments. These various diseases can also directly induce urinary symptoms, independently of urological complications. Inversely, the development of urinary disorders, especially obstructive symptoms, in a patient with Parkinsonian syndrome may require review of the neurological diagnosis. Finally, therapeutic management is complex due to the difficulty of using pharmacological treatments, and the risk of deterioration after surgical treatment of obstructive uropathy.
Collapse
Affiliation(s)
- Ph Vassel
- Centre de médecine physique et de réadaptation de Coubert, France.
| | | | | | | | | |
Collapse
|
61
|
Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord 2007; 22:220-5. [PMID: 17133504 DOI: 10.1002/mds.21253] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Deep brain stimulation in the subthalamic nucleus (STN) leads to significant improvement in motor function in patients with advanced Parkinson's disease (PD). In this prospective study including 16 patients with PD, we investigated (1) lower urinary tract symptoms (LUTS) by questionnaires International Prostate Symptom Score (IPSS, symptoms only) and Danish Prostate Symptom Score (DanPSS, symptoms and bother of symptoms) and (2) bladder control (assessed by urodynamics) before and after implantation of electrodes in the STN. PD symptoms (Unified Parkinson's Disease Rating Scale score) improved significantly (P < 0.0001), and symptoms of overactive bladder (IPSS) decreased along with the troublesome symptoms of overactive bladder (DanPSS; P < 0.01 for both). Urodynamic parameters before and after implantation of electrodes in the STN, evaluated with and without the stimulation on, did not change significantly.
Collapse
Affiliation(s)
- Kristian Winge
- Copenhagen Movement Disorders Centre, H:S Bispebjerg Hospital, Copenhagen NV, Denmark.
| | | | | | | | | | | |
Collapse
|
62
|
Affiliation(s)
- Sue Woodward
- Florence Nightingale School of Nursing and Midwifery, King's College London, 57 Waterloo Road, London SE1 8WA
| |
Collapse
|
63
|
van Leeuwen JHS, Castro R, Busse M, Bemelmans BLH. The Placebo Effect in the Pharmacologic Treatment of Patients with Lower Urinary Tract Symptoms. Eur Urol 2006; 50:440-52; discussion 453. [PMID: 16753253 DOI: 10.1016/j.eururo.2006.05.014] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2006] [Accepted: 05/09/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVES We reviewed placebo responses in randomised controlled trials (RCTs) for pharmacologic treatment of lower urinary tract symptoms (LUTS), including urinary incontinence (UI), overactive bladder, and benign prostatic hyperplasia. Review papers on placebo effects in non-urologic disorders were assessed to compare the magnitude of placebo responses in drugs for LUTS with those reported for other diseases. METHODS Data were retrieved from registration trials for LUTS drugs on the Web sites of the Food and Drugs Administration and the European Medicines Agency. Reviews were retrieved from Medline using the MeSH term "placebo effect" (English language; published between 1990 and 2005). RESULTS Placebo treatment of LUTS yields reductions in incontinence episodes (IEs) ranging from 32% to 65%, whereas prostate or UI symptom scores are reduced by 9-34%. Genuine drugs decrease IEs by 45-77% and symptom scores by 22-45%. Placebo responses are much lower when objective changes in voided volume or peak flow rate are assessed. CONCLUSIONS The placebo effect in LUTS has a strong behavioural component as patients become aware of their voiding habits and potential risk factors. Symptom severity, treatment naivety, study duration, and interaction with health care providers may also influence it. Proper patient selection, study duration, and objective and subjective outcome measures may better separate genuine treatment effects from artefacts. Observational studies with patients representative for real-life situations and covering a sufficient period of time could allow for better understanding of RCT results and their applicability in clinical practice.
Collapse
|
64
|
Female neurogenic vesicourethral dysfunction: Evaluation and management. CURRENT BLADDER DYSFUNCTION REPORTS 2006. [DOI: 10.1007/s11884-006-0002-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
65
|
Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, Sigala S, Carbone A. Correlation Between the Overactive Bladder Questionnaire (OAB-q) and Urodynamic Data of Parkinson Disease Patients Affected by Neurogenic Detrusor Overactivity During Antimuscarinic Treatment. Clin Neuropharmacol 2006; 29:220-9. [PMID: 16855424 DOI: 10.1097/01.wnf.0000228177.75711.0f] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Parkinson disease (PD) patients present urinary symptoms during the course of the disease, very often suggestive of overactive bladder and sustained by neurogenic detrusor overactivity. These symptoms cause a severe lowering of quality of life determining social withdrawal and they need to be early diagnosed to restore social interaction and prevent urinary tract complications. Today overactive bladder diagnosis is easier, thanks to the availability of new investigative tools, particularly voiding questionnaires. The aim of the present study was to evaluate the reliability of the Overactive Bladder screener (OAB screener/OAB-questionnaire), a new voiding questionnaire specifically developed for the overactive bladder diagnosis in PD subjects suffering from overactive bladder symptoms. Clinical data obtained by the questionnaire were compared with urodynamic outcomes, at basal conditions and after antimuscarinic treatment, to better explorate the questionnaire reliability. MATERIALS AND METHODS Forty PD patients have been enrolled in the protocol, and submitted to the OAB screener, voiding diary and urodynamic investigation before and after antimuscarinic treatment. OAB-score and urodynamic parameters were statistically analyzed and compared. RESULTS The OAB-q well correlated with voiding diary and urodynamic data of Parkinson subjects either at baseline or after the antimuscarinic treatment. The study suggests that this clinical tool might be used for neurogenic overactive bladder diagnosis and that it seems to be a useful outcome measure for treatments of neurogenic OAB.
Collapse
Affiliation(s)
- Giovanni Palleschi
- Department of Neuroscience, Neuro-Urology Unit, Polo Pontino, University of Rome La Sapienza, Latina, Italy
| | | | | | | | | | | | | |
Collapse
|
66
|
Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21:737-45. [PMID: 16570299 DOI: 10.1002/mds.20867] [Citation(s) in RCA: 131] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The advent of functional imaging methods has increased our understanding of the neural control of the bladder. This review examines current concepts of the role of brain function in urinary control with particular emphasis on the putative role of dopamine receptors. Dopaminergic mechanisms play a profound role in normal bladder control and the dysfunction of these may result in symptoms of overactive bladder in Parkinsonism. The importance of this nonmotor disorder has been overlooked. We address the problem of bladder dysfunction as it presents to patients and their neurologist. The prevalence of bladder symptoms in Parkinson's disease is high; the most common complaint is nocturia followed by frequency and urgency. In multiple-system atrophy, the combination of urge and urge incontinence and poor emptying may result in a complex combination of complaints. The management of bladder dysfunction in Parkinsonism addresses treatment of overactive detrusor as well as incontinence.
Collapse
Affiliation(s)
- Kristian Winge
- Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark.
| | | |
Collapse
|
67
|
Abstract
The neural mechanisms that determine social bladder control are reviewed, with a particular emphasis on the role played by sensation in the process. Much has been learnt about the neural control of the bladder from studying patients with neurological disease and those disorders that are known to disrupt bladder storage are described. Possible approaches to treatment of the resulting incontinence are reviewed and it is acknowledged that in the future, the optimal treatment for incontinence may be determined by its precise underlying pathophysiology in each instance, for example, suprapontine causes requiring different medication to spinal causes. Although the main emphasis of urological research and development so far has been the treatment of incontinence, effective therapy for other bladder disorders such an impaired emptying or bladder pain could have an important impact on the bladder symptoms of many patients.
Collapse
MESH Headings
- Animals
- Central Nervous System/physiopathology
- Cerebrovascular Disorders/complications
- Cerebrovascular Disorders/physiopathology
- Cystitis, Interstitial/etiology
- Cystitis, Interstitial/physiopathology
- Cystitis, Interstitial/therapy
- Dementia/complications
- Dementia/physiopathology
- Humans
- Multiple System Atrophy/complications
- Multiple System Atrophy/physiopathology
- Muscle Contraction
- Muscle, Skeletal/innervation
- Parkinson Disease/complications
- Parkinson Disease/physiopathology
- Spinal Cord Diseases/complications
- Spinal Cord Diseases/physiopathology
- Urethra/innervation
- Urinary Bladder/innervation
- Urinary Bladder, Neurogenic/etiology
- Urinary Bladder, Neurogenic/physiopathology
- Urinary Bladder, Neurogenic/therapy
- Urinary Bladder, Overactive/etiology
- Urinary Bladder, Overactive/physiopathology
- Urinary Bladder, Overactive/therapy
- Urinary Incontinence, Stress/physiopathology
- Urinary Incontinence, Stress/therapy
- Urination
Collapse
Affiliation(s)
- Clare J Fowler
- Department of Uro-Neurology, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG.
| |
Collapse
|
68
|
Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006; 25:116-22. [PMID: 16402391 DOI: 10.1002/nau.20193] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND AND AIMS Prevalence of lower urinary tract symptoms (LUTS) in Parkinsons disease (PD) is reported as 27%-39% based on validated questionnaires which do not consider the degree of bother. To estimate the prevalence of LUTS in patients with PD, the severity of symptoms, the volume of postmicturitional urine, and to estimate differences compared to non-PD patients referred for urological evaluation. METHODS One hundred seven patients with PD were evaluated using two sets of validated questionnaires (Dan-PSS and IPSS) about LUTS; postmicturitional residual urine was recorded, and compared to 61 patients without PD presenting at an urological clinic for examination. RESULTS Bothersome LUTS measured using Dan-PSS scores correlated significantly with Hoehn and Yahr stage of disease (P = 0.02), but not with duration of disease or age. IPSS scores did not correlate to stage of disease, duration of disease or age. Two arbitrary cut-offs were applied, identifying patients with significant LUTS, Dan-PSS > 10 and IPSS > 10. There were no significant differences between the age or duration of disease of patients with and without significant LUTS. The most frequent symptom was nocturia (IPSS: 86%) followed by frequency (IPSS: 71%) and urgency (IPSS: 68%). The most frequently reported bothersome bladder symptom was urgency (Dan-PSS: 61%), followed by nocturia (Dan-PSS: 50%) and urge incontinence (Dan-PSS: 44%). The prevalence of bothersome frequency is low (Dan-PSS: 37%). The postmicturitional volumes (PMV) did not correlate to stage of disease, duration of disease or age, or to scores on questionnaires. Mean PMV was 34 ml. Seven patients (6%) with PD had a PMV larger then 100 ml. DISCUSSION The prevalence of severe LUTS was similar with other studies, but the correlation between Dan-PSS and stage of disease, and not IPSS indicates that despite seeing no increase in frequency and severity of LUTS as PD progresses, patients find symptoms more bothersome. This may be due to progression in gait difficulties or a decreasing ability to separate and integrate sensory input, or both.
Collapse
Affiliation(s)
- Kristian Winge
- Department of Neurology, H:S Bispebjerg Hospital, Copenhagen NV, Denmark.
| | | | | | | | | |
Collapse
|
69
|
Abstract
This paper outlines the evaluation and management of neurogenic vesicourethral dysfunction (NVUD). The anatomy and neurophysiology involved with lower urinary tract functions are reviewed. Multiple sclerosis, diabetes, lumbar disc prolapse, and Parkinson's disease are specifically addressed. Proper evaluation of patients suspected of having NVUD, which is fundamental to making an accurate diagnosis, is discussed. This is followed by options for initiating individualized management plans that focus on protecting and preserving renal function, in addition to relieving the symptoms of NVUD.
Collapse
Affiliation(s)
- Rebecca J McCrery
- Scott Department of Urology, Baylor College of Medicine, 6550 Fannin Avenue, Suite 801, Houston, TX 77030, USA.
| | | |
Collapse
|